Royal London Asset Management Ltd. Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Royal London Asset Management Ltd. lifted its holdings in Boston Scientific Co. (NYSE:BSXFree Report) by 6.1% in the 3rd quarter, Holdings Channel reports. The firm owned 572,962 shares of the medical equipment provider’s stock after acquiring an additional 33,133 shares during the period. Royal London Asset Management Ltd.’s holdings in Boston Scientific were worth $30,258,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Sunbelt Securities Inc. purchased a new stake in Boston Scientific during the first quarter valued at $32,000. Motco increased its position in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new stake in Boston Scientific during the second quarter valued at $34,000. Acadian Asset Management LLC purchased a new stake in Boston Scientific during the first quarter valued at $35,000. Finally, Carolinas Wealth Consulting LLC increased its position in Boston Scientific by 2,174.2% during the second quarter. Carolinas Wealth Consulting LLC now owns 705 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 674 shares during the last quarter. Hedge funds and other institutional investors own 89.11% of the company’s stock.

Boston Scientific Trading Up 0.6 %

Shares of BSX stock opened at $67.82 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The stock’s 50 day simple moving average is $63.06 and its two-hundred day simple moving average is $56.67. Boston Scientific Co. has a 1 year low of $46.20 and a 1 year high of $68.00. The company has a market cap of $101.73 billion, a PE ratio of 63.38, a price-to-earnings-growth ratio of 2.36 and a beta of 0.78.

Boston Scientific (NYSE:BSXGet Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same period in the prior year, the business posted $0.45 earnings per share. Research analysts predict that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on BSX shares. Morgan Stanley boosted their price target on Boston Scientific from $58.00 to $61.00 and gave the company an “overweight” rating in a report on Monday, December 4th. BTIG Research reissued a “buy” rating and set a $64.00 price target on shares of Boston Scientific in a report on Friday, December 29th. Mizuho raised Boston Scientific from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $65.00 to $80.00 in a research note on Thursday, February 1st. Oppenheimer upped their price objective on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a research note on Thursday, February 1st. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.62.

View Our Latest Research Report on Boston Scientific

Insiders Place Their Bets

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 15,172 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $59.25, for a total transaction of $898,941.00. Following the transaction, the executive vice president now directly owns 56,588 shares in the company, valued at approximately $3,352,839. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 15,000 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $58.40, for a total transaction of $876,000.00. Following the sale, the executive vice president now owns 56,588 shares of the company’s stock, valued at approximately $3,304,739.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 15,172 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $59.25, for a total value of $898,941.00. Following the sale, the executive vice president now directly owns 56,588 shares in the company, valued at approximately $3,352,839. The disclosure for this sale can be found here. Insiders have sold 76,460 shares of company stock worth $4,759,945 in the last ninety days. 0.71% of the stock is owned by company insiders.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

See Also

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.